Also Known as Estraderm MX / TTS
Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
0.025mg
|
|||
Strength
0.05mg
|
|||
Strength
0.1mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Estraderm (estradiol transdermal system) is an estrogen patch used to treat the symptoms of menopause, symptoms of vulvar and vaginal atophy associated with menopause, and low estrogen levels caused by hypogonadism, castration, or primary ovarian failure. It's also used to prevent thinning and weakening of bones in postmenopausal women.
Follow the instructions that come with your Estraderm prescription. Talk to your doctor or pharmacist about any concerns or questions that arise.
Estraderm patches come in two strengths:
4 mg of estradiol USP for nominal delivery of 0.05 mg of estradiol per day
8 mg of estradiol USP for nominal delivery of 0.1 mg of estradiol per day
The Estraderm patch should be placed immediately after opening the pouch. Firmly place the adhesive side of the Estraderm patch onto clean, dry skin of the buttocks or abdomen. Avoid placing the patch on skin that is oily, damaged, or irritated. Avoid placing the patch near the waistline as clothing could rub it off. Do not expose the selected site of application to the sun. Do not place the patch on the breasts. Always discard any used patch after removal.
Change the Estraderm patch twice weekly. Always change it on the 2 days you have selected. Rotate the application sites. The same site should be avoided for at least 1 week after removing the patch. The patch will not be affected by bathing, swimming, or showering. If the patch falls off, you can put it back on and continue the original treatment scheduled. If needed, you can apply a new patch and continue the original treatment scheduled.
Keep away from children. Keep the patches in their pouches until use. Store the patches below 30°C (86°F).
Each Estraderm patch consists of four layers: a film made of a transparent polyester/ethylene vinyl acetate copolymer, a drug reservoir of estradiol USP and alcohol USP gelled with hydroxypropyl cellulose NF, a membrane made of ethylene-vinyl acetate copolymer, and an adhesive made of light mineral oil NF and polyisobutylene. In addition to these four layers, there is also a protective liner made of a siliconized polyester film that sticks to the adhesive layer; this film must be removed before using the Estraderm patch.
The active ingredient in each Estraderm patch is estradiol.
Do not use Estraderm if you:
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary emboli (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. The WHIMS estrogen plus progestin ancillary study of the WHI reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) plus MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. |
Estraderm patch side effects include breakthrough bleeding, spotting, endometrial hyperplasia, uterine leiomyomata, breast cancer, breast discomfort, breast pain, breast tenderness, high blood pressure, varicose veins, blood clot in the lungs, stomach pain, abdominal distension, abnormal liver tests, jaundice cholestatic, nausea, vomiting, diarrhea, gallstones, gallbladder problems, hair loss, skin conditions, dizziness, depression, nervousness, changes in libido, headache, migraine, back pain, extremity pain, swelling, weight changes, and allergic reactions. Contact your doctor right away if you develop side effects that bother you or won't go away.
Looking for a competitive Estraderm patch cost? With a valid prescription from your doctor, you can buy Estraderm patches online at Canada Drugs Direct.
Estraderm (estradiol transdermal system). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.